GSK
NEWS
AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits such as an improvement in cognitive function and an increased ability to perform daily tasks.
Ionis Pharmaceuticals has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion.
Hikma Pharmaceuticals generic version of Advair has hit a stumbling block with the FDA.
Realm Therapeutics announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis.
Ligand Pharmaceuticals is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences for $20 million.
Dynavax announced it has secured a $175 million non-dilutive term loan agreement to commercialize Heplisav-B.
If you had a crystal ball, you probably would have invested in Berkshire Hathaway in 1964, or Apple in the 1980s.
Since Emma Walmsley took over leadership at Glaxo, expectations have been both high and hypercritical.
Bexsero is the first vaccine in the world to receive the designation twice.
JOBS
IN THE PRESS